Back to News
Market Impact: 0.25
Tyra Biosciences Reports Positive SURF302 Results; Plans Phase 3 In LG IR NMIBC
Source: Nasdaq
Healthcare & Biotech
Tyra Biosciences reported initial results from its Phase 2 SURF302 trial of oral dabogratinib in patients with FGFR3-altered low-grade, intermediate-risk non-muscle invasive bladder cancer. The article provides no efficacy, safety, or financial data, limiting assessment of the trial's commercial or valuation implications.
AllMind Terminal
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request TrialMarket Sentiment
Overall Sentiment
neutral
Sentiment Score
0.10
Ticker Sentiment
TYRA0.45
More News
- Pharvaris at Wells Fargo conference: oral HAE drug gains ground
- Nano-X Imaging (NNOX) Q2 2026 Earnings Call Transcript
- Chewy (CHWY) Q2 2026 Earnings Call Transcript
- Kaplan Fox Encourages Investors of Beta Bionics, Inc. (NASDAQ: BBNX) to Contact the Firm to Learn About Their Legal Rights
- RNC Day 1 Kicks off in Dallas
- Kaplan Fox is Investigating Possible Securities Law Violations against Alignment Healthcare, Inc. (NASDAQ: ALHC)